Core Viewpoint - The announcement highlights a strategic collaboration between the company, Aifei Bio, and Qinhuli, focusing on the licensing of the IMD-1005 drug molecule, granting the company exclusive rights for research, production, and commercialization in specified regions [1] Group 1 - The company signed a licensing agreement with Aifei Bio and Qinhuli for the IMD-1005 drug molecule [1] - The company will pay a total of 150 million RMB as an initial payment to Aifei Bio and Qinhuli [1] - The company may pay up to 620 million RMB in milestone payments related to research and sales to Qinhuli [1] Group 2 - The company is required to pay a sales share of 12.8% to Qinhuli during the sales revenue sharing period [1]

Core Viewpoint - The company, Anglikang, plans to invest 389 million yuan in a new project to produce 8,000 tons of Amoxicillin and 2,000 tons of Ampicillin in Shengzhou, Zhejiang Province, enhancing its product layout in the anti-infection field and improving supply chain stability [1] Investment Details - The total planned investment for the project is 389 million yuan [1] - The project aims to establish self-sufficient raw material production capacity [1] Strategic Goals - The investment will strengthen the company's upstream raw material supply stability [1] - The project is expected to enhance industry chain collaboration efficiency [1] - It aims to improve cost control and market competitiveness [1] - The initiative is positioned to lay a solid foundation for sustainable development [1]

浙江昂利康制药股份有限公司 2025 年半年度报告全文 浙江昂利康制药股份有限公司 2025 年半年度报告 2025 年 8 月 1 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者实质承诺，投 资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测 与承诺之间的差异。 行业监管及行业政策变化、生产成本持续上涨、集中带量采购、环保政 策、安全生产、人才缺乏及核心技术人员流失、新产品研发、规模扩张引致 的管理风险等风险，有关风险因素已在本报告"管理层讨论与分析"部分予 以描述。上述风险提示未包括本公司可能发生但未列示的其他风险，请投资 者谨慎投资！ 公司经本次董事会审议通过的利润分配预案为：以 196,108,486 股为基数， 向全体股东每 10 股派发现金红利 1.00 元（含税），送红股 0 股（含税），不以 公积金转增股本。 2 浙江昂利康制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 ...

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company's main business involves the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - As of March 31, 2025, Anglikang reported a revenue of 346 million yuan, a year-on-year decrease of 15.31%, and a net profit attributable to shareholders of 15.91 million yuan, down 43.63% year-on-year [2]. - The company has cumulatively distributed 341 million yuan in dividends since its A-share listing, with 108 million yuan distributed over the past three years [3]. Stock Performance - On August 27, Anglikang's stock price fell by 2.04% to 51.80 yuan per share, with a trading volume of 303 million yuan and a turnover rate of 3.11%, resulting in a total market capitalization of 10.45 billion yuan [1]. - Year-to-date, Anglikang's stock price has increased by 296.69%, with a 4.75% rise over the last five trading days, a 0.38% decline over the last 20 days, and a 209.85% increase over the last 60 days [1]. Shareholder Information - As of March 31, 2025, Anglikang had 12,300 shareholders, an increase of 10.23% from the previous period, with an average of 15,104 circulating shares per shareholder, a decrease of 9.28% [2]. - Among the top ten circulating shareholders, Xinyi Medical Care A (011466) ranked as the eighth largest, holding 1.1006 million shares, a decrease of 288,300 shares from the previous period [3]. Industry Classification - Anglikang belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and chemical formulation sectors. The company is associated with concepts such as ursodeoxycholic acid, hypertension treatment, Helicobacter pylori concepts, synthetic biology, and innovative drugs [2].

Group 1 - The stock price of Anglikang experienced volatility on August 26, closing at 52.88 yuan, a decrease of 4.93% from the previous trading day [1] - Intraday, the stock reached a high of 58.93 yuan and a low of 52.69 yuan, with a total fluctuation of 11.22% [1] - The trading volume for the day was 191,000 hands, with a total transaction value of 1.055 billion yuan [1] Group 2 - Anglikang operates in the chemical pharmaceutical sector, focusing on the research, production, and sales of pharmaceutical products [1] - The company has made investments in synthetic biology and innovative drugs, positioning itself within the Zhejiang region's pharmaceutical industry [1] Group 3 - On August 26, the net outflow of main funds was 58.0946 million yuan, accounting for 0.59% of the circulating market value [1] - However, over the past five trading days, there has been an overall net inflow of 55.3316 million yuan [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.33% on August 26, with Yuan Dong Biological leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haixiang Pharmaceutical (002099) with a closing price of 6.41, up 6.13% [1] - ST Suwu (600200) with a closing price of 1.11, up 4.72% [1] - Maiwei Biological (688062) with a closing price of 42.50, up 4.14% [1] - Major decliners included: - Yuan Dong Biological (688513) with a closing price of 63.08, down 10.71% [2] - Guangsheng Tang (300436) with a closing price of 138.88, down 8.60% [2] - Shutaishen (300204) with a closing price of 56.70, down 7.05% [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 30.51 billion yuan from institutional investors, while retail investors contributed a net inflow of 18.08 billion yuan [2] - The sector's capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Haixiang Pharmaceutical (002099) had a net inflow of 78.77 million yuan from institutional investors, while retail investors saw a net outflow of 77.68 million yuan [3] - Other notable stocks with significant capital flows included: - Borui Pharmaceutical (688166) with a net inflow of 78.36 million yuan from institutional investors [3] - Yifang Biological (688382) with a net inflow of 28.31 million yuan from institutional investors but a net outflow of 89.39 million yuan from retail investors [3]

Group 1 - The innovative drug sector in the A-share market has experienced a decline, with several companies showing significant drops in stock prices [1] - Yuan Dong Biological fell over 8%, while Sunshine Nuohe dropped over 6%, and other companies like Haitai Biological and Guangshantang saw declines exceeding 5% [1] - The overall trend indicates a challenging environment for the innovative drug sector, as multiple companies are facing downward pressure on their stock performance [1] Group 2 - Specific stock performance data shows Yuan Dong Biological at -8.86% with a market capitalization of 11.4 billion, and Sunshine Nuohe at -6.99% with a market cap of 8.334 billion [2] - Other notable declines include Haitai Biological at -5.87% (7.32 billion), Guangshantang at -5.49% (22.9 billion), and Yifang Biological at -4.88% (23.2 billion) [2] - Year-to-date performance reveals that despite recent declines, some companies like Guangshantang and Aong Likang have shown substantial increases of 339.58% and 304.97% respectively [2]

Group 1 - The innovative drug sector in the A-share market has experienced a decline [1] - Yuan Dong Biological has dropped over 8% [1] - Sunshine Novo has decreased by more than 6% [1] Group 2 - Hai Te Biological and Guangsheng Tang have both fallen over 5% [1] - Yi Fang Biological, Li Fang Pharmaceutical, Kang Chen Pharmaceutical, Ang Li Kang, and Ou Lin Biological have all seen declines of over 4% [1]

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

8月25日，昂利康盘中10.01%涨停，截至10:06，报55.62元/股，成交5.37亿元，换手率5.38%，总市值 112.2亿元。 资料显示，浙江昂利康制药股份有限公司位于浙江省嵊州市嵊州大道北1000号，公司是一家集医药中间 体、原料药和制剂研发生产于一体的现代化制药企业，主要产品涵盖抗感染、心血管、麻醉镇痛等多个 治疗领域，并已建立完整的医药产业链。公司拥有多个生产基地和10余家控股子公司，是全球最大α-酮 酸原料药生产商，核心产品进入国家集中采购，近年来持续位居中国医药行业前200位。 截至3月31日，昂利康股东户数1.23万，人均流通股1.51万股。 2025年1月-3月，昂利康实现营业收入3.46亿元，同比减少15.31%；归属净利润1590.61万元，同比减少 43.63%。 ...